Back to today’s briefing

Story perspectives

AstraZeneca Considers U.S. Stock Listing to Boost Valuation

7/2/2025

40 3

Summary

Story summary

AstraZeneca's CEO, Pascal Soriot, is contemplating a bold shift of the company's stock listing from London to the U.S. This strategic move aims to attract more investors and boost valuations, potentially shaking up the UK market, which has already seen major companies exit. With a staggering valuation of $213 billion and 42% of revenue stemming from the U.S., the stakes are high.

History

Historical Context

In 2012, the London Stock Exchange faced challenges as major companies like Vodafone and Unilever considered relocating their listings, reflecting concerns about the UK market's attractiveness. AstraZeneca, valued at $213 billion, generated 42% of its revenue from the U.S., highlighting a trend of UK firms seeking better opportunities amid economic uncertainties, which could diminish the UK's status as a global financial hub.

1 of 2

Story summary

AstraZeneca's CEO, Pascal Soriot, is contemplating a bold shift of the company's stock listing from London to the U.S. This strategic move aims to attract more investors and boost valuations, potentially shaking up the UK market, which has already seen major companies exit. With a staggering valuation of $213 billion and 42% of revenue stemming from the U.S., the stakes are high.

1 / 2